JP2025506173A - 自己免疫疾患の治療のためのインターロイキン-2ムテイン - Google Patents

自己免疫疾患の治療のためのインターロイキン-2ムテイン Download PDF

Info

Publication number
JP2025506173A
JP2025506173A JP2024547537A JP2024547537A JP2025506173A JP 2025506173 A JP2025506173 A JP 2025506173A JP 2024547537 A JP2024547537 A JP 2024547537A JP 2024547537 A JP2024547537 A JP 2024547537A JP 2025506173 A JP2025506173 A JP 2025506173A
Authority
JP
Japan
Prior art keywords
fold
seq
amino acid
agent
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506173A5 (cg-RX-API-DMAC7.html
Inventor
アッシャー シャクター,
モヒット マトール,
デイビッド ウィリアム オルダッチ,
スーザン スローン,
ジル ヤーブロー,
ニコル アクラモフ,
ダイアン マ,
ウィリアム シー. タブス,
ミカエラ シュルツ,
Original Assignee
ビステラ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビステラ, インコーポレイテッド filed Critical ビステラ, インコーポレイテッド
Publication of JP2025506173A publication Critical patent/JP2025506173A/ja
Publication of JP2025506173A5 publication Critical patent/JP2025506173A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024547537A 2022-02-11 2023-02-10 自己免疫疾患の治療のためのインターロイキン-2ムテイン Pending JP2025506173A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2025506173A true JP2025506173A (ja) 2025-03-07
JP2025506173A5 JP2025506173A5 (cg-RX-API-DMAC7.html) 2026-02-19

Family

ID=85476118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547537A Pending JP2025506173A (ja) 2022-02-11 2023-02-10 自己免疫疾患の治療のためのインターロイキン-2ムテイン

Country Status (10)

Country Link
US (1) US20230390360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475875A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506173A (cg-RX-API-DMAC7.html)
KR (1) KR20240148001A (cg-RX-API-DMAC7.html)
CN (2) CN120346304A (cg-RX-API-DMAC7.html)
AU (1) AU2023219773A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243493A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009868A (cg-RX-API-DMAC7.html)
TW (1) TW202400218A (cg-RX-API-DMAC7.html)
WO (1) WO2023154870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2026154422A1 (en) * 2025-01-17 2026-07-23 Otsuka Pharmaceutical Company, Ltd. Il-2-fc fusion protein for use in treating autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
KR20240148001A (ko) 2024-10-10
TW202400218A (zh) 2024-01-01
AU2023219773A1 (en) 2024-08-01
CA3243493A1 (en) 2023-08-17
EP4475875A1 (en) 2024-12-18
CN120346304A (zh) 2025-07-22
CN119013034A (zh) 2024-11-22
MX2024009868A (es) 2024-08-20
WO2023154870A1 (en) 2023-08-17
US20230390360A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
JP7483857B2 (ja) インターロイキン-2作用物質およびその使用
AU2002305716B8 (en) Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
AU2023219773A1 (en) Interleukin-2 muteins for the treatment of autoimmune diseases
US20240108690A1 (en) Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
JP2024503506A (ja) インターロイキン-2変異体およびその使用
NZ576434A (en) Methods for treating immune disorders associated with graft transplantation with soluable CTLA4 mutant molecules
JP2024502708A (ja) インターロイキン-2作用物質を使用する方法
US20230374454A1 (en) Human immune cells genomically modified to express orthogonal receptors
WO2015112904A1 (en) Socs mimetics for the treatment of diseases
HK40113125A (en) Interleukin-2 muteins for the treatment of autoimmune diseases
HK40124714A (en) Interleukin-2 muteins for the treatment of autoimmune diseases
HK40098728A (en) Interleukin-2 mutants and uses thereof
CN116997351A (zh) 白介素-2突变体及其用途
CN116783213A (zh) Cd25偏向的抗il‐2抗体
CN111714618A (zh) T细胞和高亲和力pd-1融合蛋白的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210